InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.023

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Notification regarding unquoted securities - IMM 16 Dec 2022 3:26PM $0.315 $0.023 fallen by 92.70%
$34 Notification regarding unquoted securities - IMM 16 Dec 2022 3:25PM $0.315 $0.023 fallen by 92.70%
$34 Proposed issue of securities - IMM 15 Dec 2022 11:09AM $0.310 $0.023 fallen by 92.58%
$34 Commercial Scale in Manufacturing of Efti Achieved 8 Dec 2022 8:16AM $0.350 $0.023 fallen by 93.43%
$34 GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist 6 Dec 2022 8:59AM $0.370 $0.023 fallen by 93.78%
$34 Immutep enters 2nd collaboration with Pfizer and Merck KGaA 29 Nov 2022 8:14AM $0.350 $0.023 fallen by 93.43%
$34 Results of Meeting 23 Nov 2022 1:01PM $0.310 $0.023 fallen by 92.58%
$34 Immutep AGM 2022 - CEO's Presentation 23 Nov 2022 8:18AM $0.300 $0.023 fallen by 92.33%
$34 Immutep AGM 2022 - Chairman's Address 23 Nov 2022 8:18AM $0.300 $0.023 fallen by 92.33%
$34 Immutep Investor Update 17 Nov 2022 10:58AM $0.310 $0.023 fallen by 92.58%
$34 Immutep receives A$1 million R&D Tax Incentive 14 Nov 2022 9:18AM $0.315 $0.023 fallen by 92.70%
$34 Immutep Webcast to discuss clinical data presented at SITC 11 Nov 2022 8:16AM $0.310 $0.023 fallen by 92.58%
$34 TACTI-002 data presented at SITC for Efti in 1st line NSCLC 11 Nov 2022 8:16AM $0.310 $0.023 fallen by 92.58%
$34 INSIGHT-003 triple combination data presented at SITC 2022 11 Nov 2022 8:16AM $0.310 $0.023 fallen by 92.58%
$34 New Patents Granted in Japan and South Korea for Efti 9 Nov 2022 3:33PM $0.310 $0.023 fallen by 92.58%
$34 Abstract for Efti selected for SITC 2022 Press Conference 4 Nov 2022 9:08AM $0.320 $0.023 fallen by 92.81%
$34 Late Breaking Abstract accepted for SITC Oral Presentation 3 Nov 2022 8:33AM $0.295 $0.023 fallen by 92.20%
$34 Immutep Corporate Presentation 2 Nov 2022 12:45PM $0.290 $0.023 fallen by 92.07%
$34 Immutep to Participate in Two Upcoming Investor Conferences 2 Nov 2022 10:28AM $0.285 $0.023 fallen by 91.93%
$34 Annual Report filed on Form 20-F with SEC 1 Nov 2022 7:38AM $0.290 $0.023 fallen by 92.07%
$34 Change of Registry Address 31 Oct 2022 4:07PM $0.290 $0.023 fallen by 92.07%
$34 Independent DMC recommends to continue TACTI-003 as planned 26 Oct 2022 9:36AM $0.280 $0.023 fallen by 91.79%
$34 Quarterly Activities/Appendix 4C Cash Flow Report 25 Oct 2022 10:49AM $0.290 $0.023 fallen by 92.07%
$34 Notice of Annual General Meeting/Proxy Form 21 Oct 2022 2:37PM $0.293 $0.023 fallen by 92.14%
$34 Appendix 4G and Corporate Governance Statement 21 Oct 2022 2:26PM $0.290 $0.023 fallen by 92.07%

326 - 350 of 798 results

Page 14 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.